995-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study

Abstract

The Canadian LMC Diabetes Registry will evaluate real-world clinical outcomes in GLP-1 RA naïve patients with T2D who initiate once weekly semaglutide as part of their usual diabetes therapy in the first year of semaglutide availability in Canada. Primary outcome is change in A1C at 3 - 6 months follow-up. In this interim retrospective analysis of the first six months of semaglutide availability, 542 patients who initiated semaglutide were eligible (37% on 1.0 mg dose and 63% on 0.5 mg dose). They had a mean age of 57.3 ± 10.1 years, T2D duration of 12.0 ± 7.4 years, and baseline A1C of 8.23 ± 1.34%. At 3-6 months follow-up, 466 patients who remained on-treatment showed an A1C reduction of 0.88 ± 1.15% (p<0.01), with 36% of patients achieving an A1C reduction ≥1.0% and 43% of patients achieving A1C ≤7.0%. Similar benefit in A1C lowering was seen in subgroups based on prior diabetes therapy, concomitant insulin use and prior use of DPP-4i (Figure). Mean weight reduction was 3.1 ± 3.6 kg and 23.6% of patients achieved a weight loss ≥ 5%. Reductions were also seen for systolic BP (5.1 ± 13.0 mmHg, p<0.01), diastolic BP (2.2 ± 9.3 mmHg, p<0.01) and alanine aminotransferase (1.7 ± 12.9 U/L, p=0.03). In this real-world analysis of a large Canadian cohort, patients initiating semaglutide had significant reductions in A1C and weight at three to six months, regardless of prior and concomitant diabetes therapy. Disclosure R.E. Brown: None. A.R. Liu: Employee; Self; Novo Nordisk A/S. R. Mahbubani: Employee; Self; Novo Nordisk Inc. R. Aronson: Research Support; Self; AstraZeneca, Becton, Dickinson and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk Inc., Sanofi, Senseonics. Funding Novo Nordisk Canada Inc.